18th Jun 2014 11:00
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | AstraZeneca PLC | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | Yes | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | No | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | No | ||||
An event changing the breakdown of voting rights | No | ||||
Other (please specify): | |||||
3. Full name of person(s) subject to thenotification obligation: iii | Invesco Limited | ||||
4. Full name of shareholder(s) (if different from 3.):iv | |||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 17 April 2014 | ||||
6. Date on which issuer notified: | 17 June 2014 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 5% | ||||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
Ordinary Shares | 72,920,319 | 72,920,319 | 63,033,761 | 4.99% | ||||||||||||
GB0009895292 | ||||||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
63,033,761 | 4.99% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
Invesco Advisers Inc. - 182,047 Invesco Asset Management Japan - 75,034 Invesco Asset Management Limited - 16,790,150 Invesco Asset Management S.A (France) - 76,196 Invesco PowerShares Capital Management LLC - 158,278 Invesco GT Management Ltd - 39,146 Invesco Hong Kong Limited - 1,155 Invesco Fund Managers Limited - 45,006,926 Invesco Asset Management Limited GmbH - 667,087 Van Kampen Asset Management - 37,742 | ||
Proxy Voting: | ||
10. Name of the proxy holder: | Invesco Limited | |
11. Number of voting rights proxy holder will ceaseto hold: | N/A | |
12. Date on which proxy holder will cease to holdvoting rights: | N/A | |
13. Additional information: | ||
14. Contact name: | Sam Edwards | |
15. Contact telephone number: | 01491 416381 | |
Related Shares:
Astrazeneca